"Over 30,000 deaths a year are caused by obesity in England alone, so there is a clear need to develop a treatment to tackle this problem," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Yet this need for effective anti-obesity therapies is currently unmet. We believe that Professor Bloom's research holds great promise and, with our support, can be translated into tangible benefits to health."
Recent research by Professor Bloom and his team identified the role played by gut hormones in appetite control. These hormones are released when a person eats, acting as neurotransmitters to indicate to the brain to stop eating. In particular, the researchers are interested in pancreatic polypeptide (PP), which they believe may provide a solution to appetite suppression and is the most likely candidate for translating into a treatment.
"Developing a treatment based on natural appetite suppression, mimicking our body's response to being full, has the potential to be safe and effective," says Professor Bloom. "We believe that pancreatic polypeptide may be the answer."
Professor Bloom points to research showing that people with benign PP-secreting tumours have elevated levels of the hormone and yet appear to show no adverse side-effects.
"These people may have had high levels of PP for ten or fifteen years without showing side effects," he explains. "In that sense, they have provided us with a natural experiment that suggests that excess levels of PP over a long period are safe. It does not appear to raise blood pressure or heart rate, or any other obvious side effects."
With funding from the Seeding Drug Discovery initiative, Professor Bloom and colleague Dr Caroline Small hope to develop a synthetic form of PP which can be administered to patients.
"The trouble with PP is that it would need to be injected daily and cannot be taken as a pill," says Dr Small. "Naturally, this is not very convenient, so we need to develop an injectable form that is longer lasting and can be administered on a weekly basis to make it more practical."
If successful, the proposed research may lead to a treatment within five to eight years.
"It is likely that if we are successful, the treatment may be fast tracked to meet the urgent demand to tackle the obesity crisis," she explains. "There is currently a lack of effective treatments and our proposed drug is based on a natural way of controlling the body's appetite, which makes it more attractive."
The Wellcome Trust's Seeding Drug Discovery initiative aims to bridge the funding gap in early-stage drug discovery, assisting researchers to take forward projects in small molecule therapeutics that will be the springboard for further R&D by the biotech and pharmaceutical industry.
Craig Brierley | alfa
Gut microbiome regulates the intestinal immune system, researchers find
19.12.2018 | Brown University
Greener days ahead for carbon fuels
19.12.2018 | DOE/Lawrence Berkeley National Laboratory
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences